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1  | INTRODUC TION
Patients are confronted on a daily basis with the consequences of 
their disease and its impact on their lives. As a result, they possess 
unique knowledge—experiential knowledge—that is complementary 
to the expert knowledge of healthcare professionals and research‐
ers (Chalmers, 1995; Faulkner & Nicholls, 2001; Telford, Beverley, 
Cooper, & Boote, 2002). Caron‐Flinterman, Broerse, and Bunders 
(2005) define experiential knowledge as “the often implicit, lived 
experiences of individual patients with their bodies and their ill‐
nesses as well as with care and cure” (p. 2576).
In the period 1975–2001, there have been spectacular increases 
in survival rates of many haematological cancers (Siegel, Miller, & 
Jemal, 2016). Increased survival rates are associated with increased 
incidences of late effects of treatment (Miller et al., 2016). As a result, 
there is a growing call for the involvement of patients in oncology re‐
search and care (Efficace et al., 2012; Zucca, Sanson‐Fisher, Waller, 
Carey, & Boadle, 2017). Haematological cancer patients, often still 
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Abstract
Introduction: The experiential knowledge of patients can provide research communi‐
ties with complementary perspectives on disease. The aim of this study was to iden‐
tify and prioritise everyday problems and research needs of haematological cancer 
patients and people who have undergone a stem cell transplantation.
Methods: A	mixed‐method	 participatory	 research	 approach	 (the	Dialogue	Model)	
was applied, including interviews (n = 19), four focus group discussions (n = 27), a 
questionnaire (n = 146) and a stakeholder dialogue meeting (n = 30) with patients in 
the Netherlands.
Results: Patients’ physical discomfort, psychosocial issues, problems with the health‐
care system and policy issues were highlighted. Respondents prioritise research 
aimed at factors potentially influencing survival, such as lifestyle, and research aimed 
at improving patients’ quality of life, for example improving memory and concentra‐
tion problems. Topics also focused on physical discomfort, causal mechanisms, and 
healthcare organisation and policies. Research of a social scientific character is un‐
derrepresented, and as such, patients’ everyday problems are not all directly re‐
flected in the research agenda.
Conclusions: Our	 findings	 indicate	 that	 patients,	 besides	 emphasising	 the	 impor‐
tance of improving survival, have a clear desire to increase control over their lives.
K E Y W O R D S
haematological cancers, patient involvement, research agenda
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affected by their disease and the treatments they have undergone, 
can contribute meaningfully to the research decision‐making pro‐
cess on the basis of their experiential knowledge (Caron‐Flinterman 
et al., 2005). A validated method to both empowering patients to 
voice their experiences and needs, and providing input to research 
communities, is to establish a research agenda from the patients’ 
perspective (Abma & Broerse, 2010). Such a research agenda can 
promote a dialogue between patients, researchers, healthcare pro‐
fessionals and policymakers (Abma, 2006; Abma & Broerse, 2010; 
Pittens, 2013).
Patients are increasingly involved in the setting of research agen‐
das (Pittens, 2013). Three arguments are often used to justify patient 
involvement (Telford et al., 2002). First, the substantial argument 
highlights the complementary nature of patients’ experiential knowl‐
edge. Second, patients, as stakeholders most directly affected by the 
outcomes of scientific research, have the moral right to be involved 
in	the	decision‐making	process	concerning	their	disease	(Goodare	&	
Smith, 1995; Popay & Williams, 1996). Third, the political argument 
stresses that the involvement of patients in research increases the 
legitimacy of research because it is more consistent with the needs 
of the target population (Collins & Evans, 2002; Williamson, 2001). 
On	the	basis	of	substantial,	moral	and	political	arguments,	we	can	
hence advocate the benefits of setting a research agenda from the 
perspective of people with haematological cancer or who have un‐
dergone stem cell transplantation (SCT).1
2  | RESE ARCH PRIORITIES OF PEOPLE 
WITH HAEMATOLOGIC AL C ANCER
The research priorities of people with haematological cancer have 
only sporadically been articulated: Clinton‐McHarg, Paul, Sanson‐
Fisher,	D'Este,	and	Williamson	(2010)	and	van	Merode	et	al.	(2016)	
have investigated the research priorities of adolescents and young 
adults (AYAs) with haematological cancer and of people with mul‐
tiple	myeloma	(MM)	or	Waldenström	disease	(WD)	respectively.	In	
Clinton‐McHarg et al. (2010)’s study, AYAs prioritised: (a) clinical 
medicine aimed at finding better treatments and (b) psychosocial 
research aimed at improving physical, psychological, social and spir‐
itual outcomes for patients diagnosed with haematological cancer 
and	their	families.	Patients	with	MM	or	WD	prioritised:	(a)	improved	
communication with healthcare professionals and (b) reduced bur‐
den of neuropathy (van Merode et al., 2016).
In both of these studies, the consulted patient community 
was	relatively	confined	and	people's	everyday	problems	and	con‐
cerns regarding the consequences of their disease were not in‐
vestigated. It has been shown that enclave deliberation, namely 
the empowerment and development of a shared voice based on 
collective experiences, reduces the chance that patients are rep‐
licating media or healthcare professionals’ priorities (Nierse & 
Abma, 2011).
In this study, the everyday problems and concerns of peo‐
ple with haematological cancer were articulated prior to the 
formulation and prioritisation of their research needs in order to 
formulate a research agenda from the patients’ perspective. In 
addition to extending the results of abovementioned studies to 
a broader target population by including the perspectives of hae‐
matological cancer patients of all ages and a wider range of diag‐
noses,	the	present	study	aims	to	contextualise	people's	research	
needs with their everyday problems and concerns. This led to the 
following research questions:
1. What are the everyday problems and concerns of people with 
haematological cancer?
2. Which research themes/topics are relevant according to people 
with haematological cancer?
3. To which research themes/topics do people with haematological 
cancer give priority?
3  | METHODOLOGY
3.1 | Research approach
To involve patients in research decision‐making, a knowledge 
co‐creation process is required in which: (a) patients’ experiential 
knowledge is explicated, (b) integrated with expertise from research‐
ers and healthcare professionals and subsequently (c) embedded in 
health research, care practice and policy (Pittens, 2013; Regeer & 
Bunders, 2009). A mixed‐method participatory validated research 
approach	 to	 explicate	 patients’	 knowledge	 is	 the	 Dialogue	Model	
(Abma & Broerse, 2010; Broerse, Elberse, Caron‐Flinterman, & 
Zweekhorst, 2010). Six principles guide the model: active engage‐
ment of patients, favourable social conditions, respect for experien‐
tial knowledge, dialogue, emergent and flexible design, and process 
facilitation.	The	Dialogue	Model	originally	comprises	six	phases,	of	
which the first four were executed in this project: (a) exploration, 
(b) consultation, (c) priority setting and (d) agenda setting. The fifth 
and sixth phases (programming and implementation) of the model 
are	more	 policy‐oriented	 and	will	 therefore	 be	 part	 of	Hematon's	
follow‐up policy strategy.
The study was a collaborative effort between the Vrije 
Universiteit Amsterdam and the patient organisation Hematon. To 
optimally benefit from the knowledge co‐creation process, a project 
team was established comprising three academic researchers (au‐
thors of this study) and three Hematon volunteers (volunteer MvdB 
is also author). Within this team, all substantive decisions regarding 
the progress and the intermediate results were discussed. Two aca‐
demic	researchers	(AS	and	BdG)	were	responsible	for	the	daily	exe‐
cution of research activities. In addition to the project team, seven 
leading experts in the field of haemato‐oncology and funding agen‐
cies were invited to participate in an advisory board. All members of 
this board were interviewed prior to data collection. The board also 
met twice in plenary to provide advice on the progress of the study, 
to discuss the preliminary research findings and to assist in the im‐
plementation of the results.
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3.2 | Data collection
Data	were	 collected	 between	 January	 and	October	 2016.	 The	
study can be divided into four largely consecutive phases (see 
Figure 1).
3.2.1 | Exploration phase
Six exploratory semi‐structured interviews with patient representa‐
tives provided insights into commonly discussed everyday problems 
and concerns of the target population. Interviews were conducted in 
person, except for one interview by phone. Respondents comprised 
active volunteers for the patient organisation, who were also expe‐
riential experts.
Additionally, seven professionals from health care, research, 
funding	and	policy	were	invited	for	an	informal	interview.	During	this	
conversation, patient involvement in research in general, the proj‐
ect itself and the role and responsibilities of the advisory board for 
which they were invited were discussed.
3.2.2 | Consultation phase
Based on the findings of the exploratory phase, four focus group 
discussions	 (FGDs)	 and	 six	 additional	 semi‐structured	 interviews	
were organised to further identify everyday problems, concerns and 
research needs of the target population. A total of 33 patients took 
part (see Table 1 for more details).
Based	on	participants’	preferences,	FGDs	were	allocated	to	the	
phase of the disease:
1. people in the “Wait & See” phase of their disease, who had 
been diagnosed with haematological cancer but who had not 
received a treatment yet,
2. people who had been treated and whose haematological cancer 
was “In Remission” (but not eradicated),
3. people who were declared cured over approximately 10 years ago 
but who experienced late side effects of the treatments (“Cured, 
but late side effects”),
4. people who were undergoing treatment or who had undergone an 
SCT (“SCT/In treatment”).
Participants were recruited via Hematon, several hospitals and 
social	 care	meeting	 venues	 for	 people	with	 cancer.	 FGDs	 lasted	
2.5 hr and comprised the following parts: (a) introduction; (b) iden‐
tification of everyday problems of individuals; (c) identification of 
concerns; (d) proposing research ideas to address these problems, 
concerns and any other research topics. Any proposed solutions 
outside of the realm of scientific research were noted, but not fur‐
ther discussed.
Following	 the	 FGDs,	 additional	 interviewees	 (n = 6) were re‐
cruited through purposeful sampling to include the perspectives of 
underrepresented patient groups. These were an AYA (n = 1), some‐
one who did not suffer from a haematological cancer but who had 
undergone an SCT (n = 1) and patients in the palliative phase (n = 4). 
Interviews were conducted until data saturation was achieved. Two 
interviews were conducted face to face; the other interviews were 
conducted by phone. The interview guide was comparable to the 
FGD	set‐up.
3.2.3 | Priority setting phase
The research ideas identified during the consultation phase were dis‐
cussed within the project team to reformulate ambivalent topics and 
merge overlapping issues, and to specify broadly defined topics and 
to categorise them. The goal of this reformulation was to make the 
research topics broadly comparable and understandable to a wide 
audience; key words in each topic were briefly explained. Some 32 
research ideas were categorised into six research themes, each con‐
sisting of five to six more specifically defined topics. Prioritisation of 
the research topics by the patient community took place through a 
questionnaire. Respondents were asked to rank the topics within each 
theme and to rank the overarching themes. In addition, respondents 
could add topics that they had missed in the questionnaire. These were, 
however, not prioritised. Following the ranking, respondents were 
asked to answer questions about their haematological cancer (type 
of haematological cancer, past and current treatments) and their per‐
sonal details (age, gender, visits to meetings organised by Hematon). 
Last, respondents were asked to evaluate the questionnaire.
The questionnaires were available digitally and on paper and were pi‐
loted by three members of the target population to check comprehension, 
F I G U R E  1  Chronological	overview	of	the	4‐phased	study	along	the	lines	of	the	Dialogue	Model	(Abma	&	Broerse,	2010)
Exploratory  
interviews with  
patient  
representatives  
(n = 6)
Acquaintance  
interviews with  
members  
advisory board  
(n = 7)
4 Focus group  
discussions with  
patients (n = 27)
Additional interviews  
with young adults,  
patients in palliative  
phase, or who have  
undergone stem cell  
transplantation (n = 6)
Reflection of advisory  
board & project team  
on preliminary findings  
consultation phase
Pilot of draft  
questionnaire  
(n = 3)
Final  
questionnaire  
(n = 145)
Reflection of  
project team on  
draft questionnaire
Reflection of advisory board &  
project team on preliminary  
findings priority setting phase
Dialogue meeting  
(n = 30) Research agenda
Explorationphase Consultationphase Priority setting phase Agenda settingphase
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ease of use and relevance. Recruitment of respondents took place via 
several communication channels of Hematon and all academic hospitals 
in the Netherlands. The questionnaire was open for response for two 
months. After one month, reminder calls were sent out to members of 
Hematon to increase the response level. In total, 146 people completed 
the questionnaire. The study targeted a diversity of respondents regard‐
ing their diagnoses and treatments; in a representative sample of the 
target population, people with rare haematological cancers would only 
compose a small population of respondents (see Table 2).
3.2.4 | Agenda setting phase
The nine highest prioritised research topics were discussed at a 
three‐hour dialogue meeting at which 30 stakeholders were present, 
including patient representatives (n = 13), haematological oncology 
healthcare professionals and researchers (n = 6), and representa‐
tives from funding authorities (n = 6) and the pharmaceutical industry 
(n	=	5).	During	this	meeting,	the	topics	were	discussed	in	two	rounds	of	
small group discussions, focusing on three guiding questions: (a) What 
are the unanswered scientific questions on this topic, or does it entail 
an implementation or communicative issue? (b) What type of research 
is most relevant to solve this issue? (c) What collaborations can be use‐
ful and who is responsible? Following the discussions, a plenary session 
provided participants the opportunity to exchange the insights.
3.3 | Data analysis
The	 exploratory	 interviews	 and	 FGDs	 were	 audio‐recorded	 and	
transcribed	verbatim.	Summaries	of	interviews,	FGDs,	the	dialogue	
meeting, meetings with the project team and the advisory board 
were sent to participants for member check within 2 weeks. The 
everyday	problems	and	concerns	in	the	interviews	and	FGDs	were	
analysed through a broad interpretive thematic approach, guided 
by	the	principles	of	grounded	theory	 (Green	&	Thorogood,	2004);	
the	transcripts	were	openly	coded	by	author	[BdG]	using	ATLAS.ti	
analysis software, followed by more selective coding and catego‐
risation. Frequent discussions with the other authors of this study 
guided the exploration of the themes. The causal links and relation‐
ships between the everyday problems and concerns, as identified by 
the participants, were visualised in a problem analysis (see Figure 2).
The	qualitative	data	of	people's	everyday	problems	and	concerns	
were complemented by the quantitative analysis of the question‐
naire	results,	executed	by	the	first	author	[AS].	Research	topics	were	
ranked across themes by taking equal account of the topics’ position 
within the theme and of the themes’ ranking. This calculation of the 
allocated points resulted in a prioritised list of all research topics. In 
this system, respondents could not indicate the relative weight of 
each of their priorities; for example, the difference in importance 
of their priorities was not necessarily equal between the topics, be‐
tween the themes or between respondents. Therefore, to do justice 
to the gross prioritisation while avoiding façade precision, clusters 
of high, medium and low priority were created. The five most highly 
prioritised topics were included in the “high‐priority” category. 
Additionally, it was decided to include the highest prioritised topic T
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of each theme in this category to ensure that all themes were rep‐
resented at least once. This resulted in a “high‐priority” category 
comprising nine research topics. A similar approach was chosen to 
determine which topics belonged to the “middle‐priority” category; 
the ten next most highly prioritised topics and the next most highly 
prioritised topic of each theme were included in the “middle‐prior‐
ity” category. Twelve topics were included in this category. All eleven 
remaining topics were classified as “low priority.” It was not possible 
to statistically stratify the results. However, trends in prioritisation 
of topics along the various treatments were examined.
4  | RESULTS
In this section, we first present the results on patients’ everyday prob‐
lems and concerns as identified in the consultation phase of this study. 
This is followed by information about the prioritisation of the research 
topics. Last, the results of the dialogue meeting are briefly described.
4.1 | Analysis of everyday problems and concerns
Participants	in	the	FGDs	and	interviews	provided	a	broad	palette	of	
everyday problems and concerns with respect to their haematologi‐
cal cancer. As is illustrated in Figure 2, the issues were clustered into 
four categories: problems in/around the healthcare system, societal 
problems, psychosocial problems and physical problems. In addi‐
tion, participants identified relations between the various issues, 
and the root of the problem is presented at the bottom, leading to 
consequences higher up in the figure. A reduced quality of life is the 
ultimate	consequence	of	people's	everyday	problems	and	concerns.
4.1.1 | Diagnosis and treatment of 
haematological cancer
Participants place the haematological cancer (the diagnosis, the dis‐
ease itself and the treatments undergone) at the heart of many of 
their personal problems and concerns. In co‐morbidity situations, 
participants reported a problematic process of getting diagnosed 
correctly and rapidly. All participants indicated the disease influ‐
ences their life on various levels; the disease itself as well as the 
treatment causes physical problems, and participants also empha‐
sised the psychological impact of the disease:
It feels like you’re never really cured, it can return any 
moment.	 Do	 I	 have	 a	 year,	 or	 ten	 years	 to	 live?	 That	
uncertainty	is	hanging	above	my	head.		 (P3,	FGD	In	
Remission)
4.1.2 | Physical problems
The haematological cancer and the treatments that participants 
undergo result in a wide range of physical problems. Participants 
regard these as a complex and interdependent set of symptoms. 
Extreme and/or chronic fatigue, both cognitive and physical, is the 
TA B L E  2   Respondents of the questionnaire in the priority 
setting phase
Demographics Totalc Total %
Type of haematological cancer
AL 15 9.7
CL 38 24.7
Lymphoma 49 31.8
MDS 9 5.8
MM 25 16.2
WD 14 9.1
No disease 2 1.3
Other 2 1.3
Total 154 100
Treatment (Past and current)
Wait & See 32 15.0
Non‐intensive treatmenta 74 34.6
Intensive treatmenta 28 13.1
SCT 50 23.4
Palliative/terminal care 4 1.9
Other 25 11.7
I	don't	know	(anymore) 1 0.5
Total 214 100
Gender
Male 68 46.6
Female 78 53.4
Other 0 0
Total 146 100
Ageb
0–18 years 1 0.7
19–30 years 4 2.7
31–45 years 18 12.3
46–60 years 61 41.8
61–75 years 57 39.0
>75 years 5 3.4
Total 146 100
Visits to meetings of Hematon
No visits to meetings 60 40.5
Non‐active (annual or fewer visits to meetings) 50 33.8
Active (more frequent than annual visits to 
meetings)
19 12.8
Volunteering at Hematon 19 12.8
Total 148 100
Notes. AL: Acute leukaemia (lymphatic and myeloid); CL: chronic leukae‐
mia	(lymphatic	and	myeloid);	lymphoma	(Hodgkin	and	non‐Hodgkin);MDS:	
myelodysplastic syndrome; MM: multiple myeloma; SCT: stem cell trans‐
plantation	(allogeneic	and	autologous);	WD:	Waldenström's	disease.
aNon‐intensive treatment was translated to patients’ sphere of under‐
standing as chemotherapy, radiotherapy and/or immunotherapy in a 
room without air handling system or ship lock. Intensive treatment trans‐
lated to these treatments, in a private room with air handling system or 
ship lock. bData	collected	in	2016.	cNumbers do not always add to the 
grand total, and as in some questions, multiple answers were allowed. 
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most pressing issue discussed. For many participants, this hinders 
their daily life substantially:
Around	three	pm,	a	blanket	of	fatigue	covers	me.	[…].	
I simply can’t do anything anymore, not even drive 
home	from	work.		 (P1,	FGD	In	Remission)
There are different types of fatigue. When your body 
simply isn’t functioning, or a kind languor when I can’t 
think straight anymore. And a feeling of inertia when 
everything	just	slips	away.		 (P7,	FGD	In	Remission)
In addition to the fatigue itself, the unpredictability and invisibil‐
ity of the fatigue “the man with the hammer” hinder respondents in 
making	 and	 executing	 daily	 plans.	Other	 physical	 issues	 are	 chronic	
muscle ache (during physical effort), backache, neuropathy and plex‐
opathy, loss of sense of smell and taste, reduced fertility, reduced 
sexual potency, shingles, problems with various organs (oesophagus, 
stomach, bowels, heart, kidney, liver, lungs) and problems with wound 
healing. Furthermore, allogeneic SCT is a source of severe physical 
problems, often collected under the umbrella‐term graft versus host 
disease	 (GvHD).	Often‐mentioned	 symptoms	 of	GvHD	 are	 ophthal‐
mologic problems and extreme dryness of the skin. Participants also 
describe painful mucosa, difficulty in swallowing, and loss of hair and 
dental problems.
Furthermore, highly prevalent cognitive side effects of treat‐
ments, such as memory‐loss and concentration issues, commonly 
referred to as the “chemo‐brain,” were discussed in interviews in 
F I G U R E  2  Overview	of	causal	analysis	of	everyday	problems	and	concerns	of	people	with	haematological	cancer.	EIA:	Employees	
Insurance	Agency	[in	Dutch:	UWV].	In	blue:	problems	in/around	the	healthcare	system,	in	purple:	societal	problems,	in	orange:	psychosocial	
problems, in green: physical problems, in red: cause and (ultimate) consequence
Physical problemsPsychosocial problems
Problems in/around 
healthcare system
Societal 
problems
Ignorance of 
GPs
Ignorance E.I.A. / 
Employers
Uncertainty 
(vigilance, anxiety 
before check-ups)
Changing 
social relations 
(dependence)
Physical problems 
(fatigue, pain, 
GvHD, fertility)
Cognitive problems 
(fatigue, 
concentration-loss, 
memory-loss)
Stigma
Tension between 
daily life and ‘being a 
patient’
Dissatisfaction about 
decision-making 
responsibilities 
healthcare pathway 
Lack of 
comprehensible  
patient 
information
Lack of flexibility 
E.I.A./Employers
Anxiety for  
future
Ignorance 
outside world 
about physical 
constraints
Difficulty with 
acceptance of 
physical 
constraints
Problems with 
affordability of 
care (societally)
Perverse role of 
pharmaceutical 
industry 
Financial 
problems
Difficulties mortgages/
insurance/employment 
(job switching)
Loss of 
employment
Problems with equal 
acccessibility to care 
(societally)
Physical 
deterioriation
Worries about 
heritability for 
children
Passing untimely, 
disruption of future 
plans
Consequences of passing 
for spouses and family 
(emotionally and 
financially)
Loneliness
Discomfort in 
large company
Lack of support for 
family & spouses
Diagnosis with and 
treatment of 
HAEMATOLOGICAL CANCER
Ignorance and lack of 
empathy of haemato-
oncologists
Reduced 
quality of life
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the exploration and consultation phase. An interviewee explained 
how it had affected her professional career as she had concentration 
problems:
R2: “After the transplantation I could not multitask 
anymore. Well, especially for a woman, that’s a sur‐
prise! And it’s hard, too.”
Interviewer: “And why was this? That you didn’t 
manage?”
R2: “No oversight. Your memory needs to keep track: 
if I first do this, then I can do that next, because then 
afterwards I’ll return there… Well, that was never my 
strongest suit, but the transplantation puts a magni‐
fying glass on your weaknesses.”  (R2, Individual 
interview)
4.1.3 | Psychosocial problems
From the diagnosis throughout the course of the disease, partici‐
pants note the emotional and psychological impact of the disease 
on their lives. A poignant issue is the uncertainty that accompanies 
the disease: many participants fear its return or revival. Participants 
express an increased vigilance towards their body, and they have to 
cope with unpredictable episodes of fatigue. To them, the diagnosis 
is a lifelong sentence:
P3: “I was naive to be thinking, in a few years I’ll be my 
old self again.”
P1: “But that won’t happen…”
P3:	“Never”		 (FGD	SCT/In	Treatment).
The fear of an untimely death also disrupts participants’ future 
plans. Concerns about their own death are often linked to worries 
about the practical, financial and emotional well‐being of their family 
members:
For	my	spouse,	 it	[untimely	death]	will	be	a	financial	
burden,	 I	think,	 […]	She	will	have	to	continue	on	her	
own. The children will miss their dad. They are a little 
older	[…]	but	still,	losing	your	father	at	that	age	is	ter‐
rible.		 (P5,	FGD	Wait	&	See)
Acceptance	of	one's	physical	constraints	and	deterioration	is	often	
experienced as difficult. Participants feel a tension between their lives 
“as a patient” and their daily routines:
You’re living in two worlds, so to say. There is the 
world of being a patient, having been diagnosed and 
frequently visiting the hospital for check‐ups. Lying in 
bed in the morning, thinking: what am I feeling? Is this 
a warning sign? And then there is just my normal life, 
going to work and fully enjoying all the fun things of 
life.		 (P7,	FGD	Wait	&	See)
Also, social relations with spouses and relatives change as par‐
ticipants are apprehensive of becoming emotionally and practically 
dependent due to physical deterioration. Marriage is often put to the 
test, as partners are also affected:
You don’t get cancer by yourself, you have to fight it to‐
gether	[as	spouses].	If	you	both	deal	with	the	anxiety	in	a	
different way, there are two parallel circuits. That can be 
harder	than	expected.		 (P4,	FGD	In	Remission)
Related to changing social relationships, loneliness is fuelled by 
societal	problems,	such	as	loss	of	employment,	as	well	as	by	people's	
physical fragility and by restrictions on being in large groups due to 
the suppressed immune system after treatment:
After the transplantation from a donor, you have to 
follow	a	number	of	commands.	[…]	Don’t	go	to	the	su‐
permarket,	no	theatre	visits,	[…].	If	you	have	visitors,	
no more than 6 in your living room, etcetera. In the 
beginning, you agree to take these measures until you 
grow stronger and you don’t have to take medication, 
which suppresses your immune system anymore. But 
2.5	years	 later,	 I’m	 still	 on	 this	medication.	 […]	 It’s	 a	
lonely life.  (R4, individual interview)
4.1.4 | Problems in/around healthcare system
Participants have unmet expectations of their healthcare providers. 
Ignorance and a lack of empathy of haematological oncologists are 
frequently mentioned. Many participants feel they are not treated 
as a person; they experience a lack of recognition and understanding 
for what they, as patients, are going through:
It’s tough, but in the medical world we are all just a 
number.		 (P2,	FGD	Cured,	late	side	effects)
For their relatives, support is even scarcer. Although participants 
can show an understanding of their specialists’ professional distance, 
unclear, incomprehensible and ill‐timed information provision means 
that less support is available to them. Following hospital discharge, par‐
ticipants are often especially disappointed by the limited knowledge 
of	 their	 family	doctor	 (GP)	 regarding	 their	disease	and	 its	 long‐term	
consequences:
Then	you	arrive	at	the	GP	on	duty	[…]	and	sometimes	
they will draw conclusions which don’t make any 
sense at all. Then you’ll think, whatever, I’ll just go 
back	home.		 (P2,	FGD	SCT/In	Treatment)
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Regarding participation in decisions regarding healthcare, some 
participants feel that other patients should take more control. 
However, not everyone wants shared decision making; some peo‐
ple prefer to hand over all responsibility to their treating physician. 
Especially in acute situations, it can be difficult to make decisions with 
long‐lasting consequences, for example regarding treatment options 
which can affect patients’ fertility:
“Sometimes you have to decide within 4 hours for the 
rest of your life!” [regarding a fertility‐saving surgical 
procedure]		 (P6,	FGD	SCT/In	Treatment)
4.1.5 | Societal problems
Many participants consider the word “cancer” stigmatising; bystand‐
ers are said to “jump on the brakes” when they hear about the diag‐
nosis.	A	respondent	explains	that	the	treatments	and	severe	GvHD	
have	changed	her	appearance.	On	the	streets,	people	stare	at	her,	
express their unsolicited compassion or seem to gossip about her. 
Her children are told by peers their mother looks “weird.” Such ex‐
periences add to tension between participants’ “daily life” and their 
“patient life,” increasing their loneliness.
In addition to the stigma, participants face incomprehension as 
their disease is “invisible,” while their physical constraints are not:
People don’t see from the outside that you’re ill on 
the inside. That is difficult, also for the outside world. 
	 (P3,	FGD	Cured,	late	side	effects)
In addition, many participants experience problems at work. 
Provision of alternative employment or adjusted employment circum‐
stances is often problematic, and employers are afraid their sick em‐
ployee will be expensive. Some participants report disputes with their 
employers,	during	which	support	is	lacking.	Often,	loss	of	employment	
is particularly painful as participants would like to maintain an active 
role in society:
Well I do remember, the moment I received that call 
from	 the	UWV	 [employee	 insurance	 agency]	 to	 tell	
me I was unfit for work, yes that gave me some good 
cries.		 (P1,	FGD	SCT/In	Treatment)
Participants criticise the lack of flexibility and the ignorance of the 
Employee	 Insurance	Agency	 (in	Dutch:	UWV),	which	 is	 the	govern‐
ment agency responsible for helping unemployed people find suitable 
work:
You’re simply in a treadmill, and you’re being sent from 
pillar to post. My situation is rather extraordinary be‐
cause my employer doesn’t want to discharge me, be‐
cause he then needs to pay a transition fee, even when 
the employee has been ill for two years. That is very 
demotivating.		 (P4,	FGD	SCT/In	Treatment)
These factors contribute to the loneliness experienced by partici‐
pants. In addition, the financial aspect of participants’ inability to work 
is discussed. Insurance sometimes covers participants’ loss of income 
insufficiently	on	the	long	term.	Gaining	a	mortgage	or	taking	out	new	
insurance	can	be	problematic	because	of	people's	medical	record,	re‐
ducing their financial status further.
4.1.6 | Anxiety for the future and a diminished 
quality of life
As the haematological cancer directly affects personal futures, par‐
ticipants describe an anxiety about their future, diminishing their 
current quality of life. In addition, factors such as loneliness and 
difficulty with accepting physical deterioration contribute to an ex‐
perienced lower quality of life. Many participants fear physical dete‐
rioration, dependence on family or social care, and a long and painful 
deathbed:
For me, I’m worried to die in a really ugly way.
Interviewer: “What do you mean with ugly?”
Well, that your body really collapses and that you get 
a lot of pain, and that you can’t do anything anymore. 
And that the family also can’t take it any longer.  (P3, 
FGD	In	Remission)
They also want to receive more, truthful information about the pal‐
liative phase of their care pathway. Participants with a strong desire 
to stay independent expressed the wish to commit euthanasia when 
necessary.	On	a	societal	 level,	participants	are	concerned	about	 the	
continued accessibility and affordability of health care, acknowledging 
the high costs of treatment and low prevalence of specific diseases. 
However,	these	issues	are	discussed	with	less	urgency	than	people's	
more personal worries.
4.2 | Research agenda
In this section, the quantitative analysis of the prioritised research 
needs is presented. This prioritisation is interpreted with the input 
gathered during the consultation phase and the dialogue meeting. 
All research themes and individual topics on the research agenda are 
presented in Table 3.
In the high‐priority cluster, the top‐5 topics belonged to two 
main research themes; “factors influencing survival” (24.6% of all al‐
located points) and “improving well‐being and quality of life” (20.8% 
of allocated points). The methodological choice was made to include 
one topic of each of the other four research themes (“relieving phys‐
ical discomfort,” “understanding mechanisms of disease,” “improving 
organisation of healthcare (system),” “policy issues”) in the highest 
priority category. These topics are marked with an * in Table 3. These 
themes were awarded 17.9%, 14.9%, 12.3% and 9.5% of the allo‐
cated points respectively. Below, we elaborate on the topics that 
were assigned to the high‐priority category.
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4.2.1 | Factors influencing survival
The role of lifestyle was the highest prioritised topic in this theme. 
To	participants	in	FGDs,	lifestyle	revolves	around	the	prevention	of	
the disease, as well as improving the quality of life and chances of 
survival. The underlying experienced problem contributing to this 
research topic is a lack of control in the occurrence and course of the 
disease; participants feel they can fight their feelings of helplessness 
and passivity by taking control of their lifestyle:
Well I think nutrition gives you some hold on life, and I 
think it’s nice to have the idea that you can actually do 
something, next to taking all these terrible pills.  (P4, 
FGD	SCT/In	Treatment)
The topic of the effects of standardised check‐ups on survival was 
also highly prioritised. Participants describe a level of arbitrariness in 
the continuation of check‐ups after they have been declared cured, 
while their vigilance continues to exist:
There	 is	 this	 vigilance,	 you’re	 continually	 alert.	 [...].	
It’s difficult whether to take yourself seriously, you 
keep wondering whether you’re a hypochondriac or 
whether it is wise to be on the alert all the time.  (P2, 
FGD	Cured,	late	side	effects)
Participants	to	FGDs	advocate	research	 into	the	effects	of	stan‐
dardisation of aftercare. Also, they would like to improve the efficacy 
of these check‐ups and be provided with information regarding the late 
side effects of treatments. Some participants experience the check‐
ups as an emotional burden because it reminds them of the possible 
return of the disease.
Participants also highly prioritised research into the role of en‐
vironmental context on survival. “Environmental conditions” can 
vary between bacteria in the domestic sphere, toxic substances or 
air pollution, and research can span the influence of environmental 
conditions on the occurrence of the disease, as well as its effect on 
people's	survival	after	treatment.
4.2.2 | Improving well‐being and quality of life
Improving memory and concentration problems (“chemo‐brain”) is 
highest prioritised in this theme. Research questions can focus on the 
mechanism of occurrence, prevalence and effective relief strategies. 
For example, in the consultation phase, an interviewee was curious 
about the efficacy of existing or new training schemes, such as neuro‐
feedback training, to improve patients’ memory and concentration.
The lack of emotional and practical support for participants’ fam‐
ily	members	was	an	often‐mentioned	issue	in	the	FGDs.	Participants	
want to know which support schemes can be effective in improving 
the well‐being and quality of life of their spouses and children, and 
how this would affect their own quality of life. Attendees at the di‐
alogue meeting agree that haematological oncologists generally pay 
little attention to the emotional well‐being of family and friends, 
assigning such care to the oncological nurse mentoring the patient.
4.2.3 | Relieving physical discomfort
Relieving the long‐term side effects of treatments was considered 
the most important research topic in this theme. Participants who 
were diagnosed and treated for their haematological cancer in the 
distant past face ignorance and a lack of interest in relieving the 
long‐term side effects of the treatments:
I notice that physicians and researchers prefer to focus 
on the large group of patients with whom they can truly 
achieve something in the curation part. The late effects, 
especially when the numbers of patients are small, then 
it gets tricky. Every time I hear again, we’re sorry, but 
we don’t know what your risk is because we’ve never 
studied	it.		 (P2,	FGD	Cured,	late	side	effects)
As the survival rates of people with haematological cancer have 
increased, the group of survivors experiencing late side effects is 
growing. Attendees at the dialogue meeting suggested utilising an 
existing database of side effects of treatments to map out more 
extensively the side effects of current and new treatments. Their 
rationale was that only when the late side effects are properly inven‐
toried will it be possible to study how to relieve them.
4.2.4 | Understanding mechanisms of disease
Many participants highly prioritised the topic of “personalised medi‐
cine,” namely treatment approaches aimed at customising the therapy 
to the individual patient to maximise its chance of success and reduce 
overtreatment. This topic was classified as fundamental research be‐
cause it includes recent developments in, for example, immunotherapy. 
To some participants, immunotherapy was a “buzzword” because they 
were particularly interested in improving their chances of being cured:
Now	 that	 immune	 system,	 [...]	 directed	 by	 immuno‐
therapy, that is supposedly the	 solution.	 [...]	 It’s	 the	
personalised solution to make your immune system 
work for you to destroy those cancerous cells.  (P2, 
FGD	Wait	&	See)
Attendees at the dialogue meeting plead for international col‐
laborations to encourage a focus on this research topic. At the same 
time, they warn against false hope; they consider it the responsibil‐
ity of patient organisations and haematological oncologists alike to 
temper the high expectations of some patients regarding this topic.
4.2.5 | Improving organisation of healthcare 
system and policy issues
More interdisciplinary collaboration between medical and non‐med‐
ical professionals, such as haematological oncologists, psychologists, 
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TA B L E  3   All research topics under the accompanying research theme, with relative importance of each topic within the theme and the 
relative importance of the themes as well as the assigned priority clusters
Assigned priority 
cluster
Relative priority 
topics (%)
Relative priority 
theme (%)
Theme: Factors influencing survival
The role of lifestyle on survival High 23.8 24.6
The effect of standardised check‐ups on survival High 22.9
The role of environmental conditions on survival High 19.3
The effect of vaccinations on survival Middle 18.0
The effect of self‐medication on survival Middle 16.0
Total 100
Theme: Improving well‐being and quality of life
Improving memory and concentration problems due to treatments High 29.7 20.8
Improving the support of spouses and family High 21.7
The role of a sense of meaning on patients’ quality of life Middle 18.9
Dealing	with	changes	in	need	for	physical	intimacy	as	a	consequence	of	
diagnosis and treatment
Middle 15.8
The contribution of emotional support to patients’ quality of life Middle 13.9
Total 100
Theme: Relieving physical discomfort
Relieving the long‐term side effects of a variety of treatments Higha 21.9 17.9
Relieving chronic fatigue Middle 20.4
The prevention of overtreatment Middle 16.3
Relieving	the	symptoms	of	GvHD	after	SCT Middle 15.7
The effect of rehabilitation on the physical discomfort due to 
treatments
Middle 14.7
The effect of treatment on physical sexuality Low 10.9
Total 100
Theme: Understanding mechanisms of disease
Focusing treatments on individual patients. High a 20.8 14.9
The causal mechanisms of haematological cancers Middle 20.4
The functioning of new medication in practice Low 17.4
The	emergence	and	prevention	of	GvHD	after	SCT Low 15.2
The relationship between haematological cancers and other disorders Low 13.8
The differences between men and women in getting a haematological 
cancer, and how they are affected by treatments
Low 12.4
Total 100
Theme: Improving organisation of healthcare system
The effect of an interdisciplinary approach to haematological cancer on 
the well‐being of the patient.
Higha 24.1 12.3
Improving the decision‐making with patients concerning acute topics Middle a 21.6
Improving the knowledge of extramural healthcare professionals (e.g. 
the	GP),	about	haematological	cancers	and	its	treatments
Low 19.4
The effect of a care‐coordinator on the well‐being of patients Low 18.0
Changing the “directive‐culture” in the organisation of haematological 
oncology care
Low 16.9
Total 100
(Continues)
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social workers and occupational physicians, was the highest priori‐
tised topic in this theme. In the consultation phase, many partici‐
pants brought to the fore that such collaboration is important for 
improvement of the well‐being of patients:
If you don’t exactly fit the bill, then it gets compli‐
cated. And these multidisciplinary teams don’t func‐
tion	properly	yet.		 (P1,	FGD	Wait	&	See)
Some participants broaden this collaboration by specifically 
calling for a holistic view of the patient and the inclusion of com‐
plementary medicine practitioners to the range of collaborating 
healthcare professionals. Participants also note differences be‐
tween hospitals in the interpretation of rules and regulations re‐
garding funding and accessibility of treatments and medication. 
They therefore prioritise the preservation of equal accessibility to 
medication and treatment.
4.3 | Stratification of research priorities
Although no statistical stratification could be attempted due to the 
small number of respondents, it was possible to observe prioritisa‐
tion trends in the largest treatment groups (see Table 1): Wait & See 
phase, non‐intensive treatment; intensive treatment; and SCT. The 
group of respondents who had received or were receiving palliative 
care was too small (n = 4) to be meaningfully included in this strati‐
fication, while the group “other” (n = 25) was presumed too diverse. 
No change in prioritisation of the overall research themes was ob‐
served. However, a shift in a few research topics could be found; for 
example, people in the Wait & See phase give less prominence to the 
topic “Relieving the long‐term side effects of a variety of treatments” 
than other respondents. Also, prevention and relief of the symptoms 
of	GvHD	are	especially	highly	prioritised	by	people	who	have	un‐
dergone an SCT. These shifts in priority are not surprising given 
the stage of respondents’ disease. Albeit limited, this stratification 
indicates that most priorities are shared equally across the different 
groups of respondents.
4.4 | Dialogue meeting
At the dialogue meeting, all highly prioritised research topics were 
discussed in small groups. Additionally, the research agenda and im‐
plications for its implementation were discussed plenary. Attendees 
noted	 that	 some	 research	 topics	 are	 confined	 to	 the	 Dutch	 situa‐
tion. For example, more interdisciplinary collaboration in the health‐
care system is considered to be a context‐specific research topic. 
Attendees considered that several research topics call for an inter‐
national approach as the findings can be generalisable and the costs 
for clinical research are generally high (e.g. personalised medicine). In 
addition, they agreed that the next steps regarding the research top‐
ics are variable. Some topics need more research attention, such as 
relieving long‐term side effects of treatment. In other cases, health‐
care professionals and researchers could benefit from knowledge 
generated outside of haematological oncology. For example, support 
structures for patients’ spouses and families could be based on similar 
schemes	in	practice	in	breast	cancer	care.	On	the	whole,	the	attend‐
ees at the meeting expressed their willingness to assist in the imple‐
mentation of the research agenda and they were all eager to continue 
the dialogue with Hematon on further collaboration.
5  | DISCUSSION
The research themes presented in this study generally correspond 
to the earlier work on research priorities of people with haemato‐
logical cancers, as investigated by Clinton‐McHarg et al. (2010) and 
Merode et al. (2016). The most highly prioritised research themes 
identified in our study correspond to the findings of Clinton‐
McHarg et al. (2010), namely that AYAs with haematological can‐
cer prioritise clinical medicine and psychosocial research. This also 
Assigned priority 
cluster
Relative priority 
topics (%)
Relative priority 
theme (%)
Theme: Policy issues
The preservation of equal accessibility to medication and treatment Higha 24.9 9.5
Reducing the costs of medication Middlea 21.5
The effect of the regulation and deregulation of the pharmaceutical 
industry on the development and accessibility of medication
Low 18.5
The evaluation of policy aimed at “orphan drugs” b Low 18.3
Improving the societal support of patients Low 16.9
Total 100
Total 100
aThe topic is assigned to the “high‐priority” or “middle‐priority” cluster as the topic was prioritized highest or next‐highest within the theme, but it does 
not belong to the top‐5 highest or top‐10 next‐highest prioritized topics, respectively. bOrphan	drugs	are	drugs	for	rare	diseases,	for	which	the	phar‐
maceutical	industry	receives	governmental	R&D	support	due	to	low	expected	revenues.	
TA B L E  3   (Continued)
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links to the strained balance between spending research money on 
improvement of survival rates and on improving patients’ quality 
of life. However, as the study by Clinton‐McHarg et al. (2010) does 
not specify any subdomains except psychosocial research, a more 
fine‐grained comparison with our findings is difficult. Merode et al. 
(2016) investigated the research priorities of people with MM or 
WD.	The	prominence	of	the	problems	in	the	healthcare	system	as	
encountered in the consultation phase of our study resembles their 
conclusion that “aspects concerning communication (involving the 
patients in decision making process, supplying good information, 
having good communication skills) were regarded as very important 
by the participants” (van Merode et al., 2016, p.15). However, the 
prioritisation of the topics by respondents in the study of Merode 
et al. (2016) differs somewhat from our study because communica‐
tion problems were not prioritised highly by our participants.
On	 the	 research	 agenda,	 a	 number	 of	 topics	 are	 specific	 for	
haematological cancers. Research to alleviate physical discomfort 
caused	by	treatments,	in	particular	the	side	effects	of	GvHD,	is	quint‐
essential for haemato‐oncology, and it could contribute to improv‐
ing patients’ health‐related quality of life (Frodin, Lotfi, Fomichov, 
Juliusson, & Borjeson, 2015). However, research into other everyday 
problems and research needs, such as employment, fatigue, well‐
being, regaining control and lack of support for patients’ relatives, 
can be, and increasingly are, addressed by the general oncological 
research field (Curt et al., 2000; Kim, 2007; Stenberg, Ruland, & 
Miaskowski, 2010). Participants’ complaints about impersonal care 
and a lack of empathy of physicians are consistent with general lit‐
erature on oncological patients’ perspectives on good‐quality care 
(Attree, 2001). Last, similar to our participants, US oncological pa‐
tients also experience direct and indirect financial costs of cancer 
care on top of the emotional and physical hardships of the disease 
itself (Kim, 2007). This indicates that some everyday problems and 
research needs may transcend the national health systems’ context.
5.1 | Contextualisation of the main research findings
A strength of the present study is the contextualisation of patients’ 
research needs in the light of their everyday problems and concerns. 
For example, the research priority “effect of lifestyle on survival” 
indicates that people with haematological cancer have the desire 
to gain control over their lives. Patients want evidence‐based direc‐
tives to change their lifestyle as they want to combat their sense 
of helplessness. Similarly, the topic “physical (late) side effects of 
treatment” was intensively discussed during the consultation phase, 
and research into relieving this burden was highly prioritised.
Disparities	between	the	FGDs/interviews	and	prioritisation	of	
the research topics can also be observed. For example, participants 
in the consultation phase discussed frustrations about healthcare 
provision and societal issues, such as employment issues and fi‐
nancial troubles, as an additional burden on top of the distress of 
the disease itself. However, these topics were not highly prioritised 
on the research agenda. Instead, respondents in the priority set‐
ting phase put more emphasis on the importance of understanding 
factors influencing survival. A possible explanation for this dis‐
parity could be that the participants’ wish to cure the disease was 
regarded	 as	 self‐explanatory	 in	 FGDs	 and	 interviews.	 The	 ques‐
tionnaire indicates that the implicit emphasis on improving survival 
in the consultation phase should not be mistaken for a low priority.
The contextualisation of patients’ research needs reveals that a 
direct relationship with patients’ everyday problems and concerns 
cannot be assumed. Patients may consider other strategies than 
research (e.g. policy measures) more appropriate to address cer‐
tain everyday problems, whereas research topics may be prioritised 
without addressing one specific everyday problem or concern (e.g. 
personalised medicine). Although it is beyond the scope of this arti‐
cle, it could be interesting to examine more in depth to what extent 
patients’ lived experiences are complemented by public discourse 
or replication of their healthcare providers’ opinion, and to what 
extent	 people's	 prioritisation	 is	motivated	 solely	 by	 their	 experi‐
ential knowledge or also by other sources of information. Studies 
on the medicalisation and pharmaceuticalisation of society (e.g. 
Williams,	Martin,	&	Gabe,	 2011),	 on	 enclave	 deliberation	 (Nierse	
& Abma, 2011) and on effective inclusion strategies for patients in 
knowledge co‐production processes (Elberse, Caron‐Flinterman, & 
Broerse, 2011) can be valuable in this debate as they all explore the 
nature of experiential knowledge from a different point of view.
5.2 | Methodological considerations
The mixed‐method approach, in which everyday problems and con‐
cerns	and	research	topics	were	covered	in	depth	by	FGDs	and	inter‐
views and in breadth by the questionnaire, is one of the strengths 
of this study. Through our methodological approach, we have at‐
tempted to stay as close to the lived experiences of the target popu‐
lation as possible. The combination of close collaboration throughout 
the project with patient representatives on the one hand, and includ‐
ing patients without any representative function in the consultation 
and priority setting phase on the other, has contributed to this ef‐
fort. By stimulating enclave deliberation (Nierse & Abma, 2011) and 
by paying attention to verbal, behavioural and circumstantial inclu‐
sion strategies for patients (Elberse et al., 2011), the results provide 
a rich account of the patient perspective.
During	the	study,	some	difficulties	were	encountered	regard‐
ing	the	recruitment	of	patients	for	the	FGDs.	As	a	result,	two	sep‐
arately	planned	FGDs	(“SCT”	and	“in	treatment”)	yielded	too	few	
patients	and	were	therefore	merged	in	one	FGD.	To	achieve	data	
saturation, six additional interviews were organised with under‐
represented groups of participants. In these interviews and in the 
questionnaire, few new topics emerged, indicating data satura‐
tion. The questionnaire also yielded fewer respondents than we 
had aimed for. As a result, we were obliged to dispense with sta‐
tistical stratification of the research topics. Additionally, it should 
be noted that the survivors of potentially deadly haemato‐onco‐
logical disease were found to value research into well‐being, while 
it is possible that those who have died might have placed greater 
emphasis on finding a cure for the disease.
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Although we attempted to cover this knowledge gap by inter‐
viewing several people in the palliative phase, it is possible that the 
emphasis of the entire patient population on a cure is underestimated.
Last, the methodology paid no explicit attention to cost‐benefit 
ratios of different research topics or to the international research 
landscape. Research costs were discussed in meetings with the 
advisory	board,	 in	a	number	of	FGDs	and	at	the	dialogue	meeting.	
In the priority setting phase, however, respondents’ attention was 
not diverted to optimising resource allocation strategies but in‐
stead focused on their research needs, irrespective of financial, or‐
ganisational or logistical constraints. It is proposed to include this 
dimension more extensively in the next steps regarding the imple‐
mentation of the research agenda.
5.3 | Recommendations for implementation
To move from a research agenda to effective implementation of the 
prioritised themes, a number of recommendations can be formu‐
lated. As described by Pittens, Elberse, Visse, Abma, and Broerse 
(2014), collaborations with researchers, healthcare professionals 
and funding agencies should be encouraged to get to the heart of 
the various research topics. Such dialogues facilitate the effective 
implementation of the research agenda into research practice. In 
the follow‐up, programming phase, Hematon will contact relevant 
teams of researchers and healthcare professionals in order to 
translate the research themes into specific topics and questions. 
The dialogue meeting can be considered a fruitful starting point for 
this endeavour, as it kindled enthusiasm for the research agenda 
amongst key stakeholders in the field, including researchers, poli‐
cymakers and members of scientific advisory board. Keeping the 
momentum is crucial in this phase; as other stakeholders need time 
to become accustomed to the inclusion of the patients’ perspec‐
tive, the timing of the research agenda in relation to developments 
in the field is important (Pittens et al., 2014). With this research 
agenda, Hematon possesses a valuable tool to obtain a seat at the 
decision‐making table, thus empowering their patients’ position.
6  | CONCLUSIONS
This study aimed to formulate a research agenda by and for people 
with haematological cancer by investigating the everyday problems 
and concerns of the target population with regard to their disease, 
and by identifying and prioritising research themes from their per‐
spective. The study yielded a wide range of interconnected prob‐
lems and concerns. At the individual level, participants experience 
a cascade of psychosocial and physical issues due to the diagnosis, 
the disease itself and the accompanying treatments. Fatigue is dis‐
cussed as requiring urgent research attention, as well as the feel‐
ing of uncertainty which participants experience. In addition, fear 
of physical deterioration and changing social relations, especially 
losing	 one's	 independence,	 contribute	 to	 people's	 anxiety	 about	
the future. Societal issues, such as ignorance and lack of flexibility 
amongst employers, and troubled interactions with healthcare pro‐
viders, are also mentioned. These factors contribute, directly or in‐
directly, to participants’ experienced reduction in quality of life.
The highly prioritised topics on the research agenda indicate that, 
in addition to improving patients’ experienced well‐being, question‐
naire respondents want resources to be allocated to research into 
lifestyle factors contributing to improved survival rates. Research 
into mechanisms of disease, and research of a social scientific nature 
into the organisation of healthcare and related policy issues, is prior‐
itised to a lesser extent.
7  | COMPLIANCE WITH ETHIC AL 
GUIDELINES
No	approval	of	an	accredited	Dutch	medical	research	ethics	commit‐
tee was needed for this study as it did not involve medical research 
or any form of invasion of the participants’ integrity. Throughout 
the course of the study, the privacy and confidentiality of all par‐
ticipants’	 contributions	were	 respected;	 the	 interviews	and	FGDs	
were recorded after verbal consent and all transcripts, summaries 
and	contributions	to	the	questionnaire	were	anonymised.	Only	two	
researchers	(BdG	and	AS)	had	access	to	the	keys	of	the	transcripts.
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ENDNOTE
1For the purpose of conciseness, we will refer to the target population 
(people with a haematological cancer and/or who have undergone a 
stem cell transplantation, or who have been declared cured of such a 
disease) as “people with a haematological cancer.” 
ORCID
Anne‐Floor M. Schölvinck  https://orcid.
org/0000‐0001‐7462‐7381 
R E FE R E N C E S
Abma, T. A. (2006). Patients as partners in a health research 
agenda setting: The feasibility of a participatory methodology. 
Evaluation and the Health Professions, 29(4), 424–439. https://doi.
org/10.1177/0163278706293406
14 of 14  |     SCHÖLVINCK et aL.
Abma, T. A., & Broerse, J. E. W. (2010). Patient participation as dialogue: 
Setting research agendas. Health Expectations, 13(2), 160–173. 
https://doi.org/10.1111/j.1369‐7625.2009.00549.x
Attree, M. (2001). Patients’ and relatives’ experiences and perspectives 
of “good” and “not so good” quality care. Journal of Advanced Nursing, 
33, 456–466. https://doi.org/10.1046/j.1365‐2648.2001.01689.x
Broerse, J. E. W., Elberse, J. E., Caron‐Flinterman, J. F., & Zweekhorst, M. 
B. M. (2010). Enhancing a transition towards a needs‐oriented health 
research system through patient participation. In J. E. W. Broerse, 
&	 J.	 F.	G.	 Bunders	 (Eds.),	Transitions in health systems: Dealing with 
persistent problems (pp. 181–208). Amsterdam, the Netherlands: VU 
University Press.
Caron‐Flinterman,	J.	F.,	Broerse,	J.	E.	W.,	&	Bunders,	J.	F.	G.	(2005).	The	
experiential knowledge of patients: A new resource for biomedical 
research? Social Science and Medicine, 60(11), 2575–2584. https://
doi.org/10.1016/j.socscimed.2004.11.023
Chalmers, I. (1995). What do I want from health research and researchers 
when I am a patient? British Medical Journal, 310, 1315–1318.
Clinton‐McHarg,	T.,	Paul,	C.,	Sanson‐Fisher,	R.,	D’Este,	C.,	&	Williamson,	
A.	 (2010).	 Determining	 research	 priorities	 for	 young	 people	 with	
haematological cancer: A value‐weighting approach. European 
Journal of Cancer, 46(18), 3263–3270. https://doi.org/10.1016/j.
ejca.2010.06.013
Collins, H. M., & Evans, R. J. (2002). The Third Wave of Science Studies: 
Studies of Expertise and Experience. Social Studies of Science, 32(2), 
235–296.
Curt,	 G.	 A.,	 Breitbart,	 W.,	 Cella,	 D.,	 Groopman,	 J.	 E.,	 Horning,	 S.	 J.,	
Itri, L. M., … Vogelzang, N. J. (2000). Impact of cancer‐related fa‐
tigue on the lives of patients: New findings from the Fatigue 
Coalition. The Oncologist, 5(5), 353–360. https://doi.org/10.1634/
theoncologist.5‐5‐353
Efficace, F., Cocks, K., Breccia, M., Sprangers, M., Meyers, C. A., Vignetti, 
M., … Mandelli, F. (2012). Time for a new era in the evaluation of 
targeted therapies for patients with chronic myeloid leukemia: 
Inclusion of quality of life and other patient‐reported outcomes. 
Critical Reviews in Oncology/Hematology, 81(2), 123–135. https://doi.
org/10.1016/j.critrevonc.2011.02.007
Elberse, J. E., Caron‐Flinterman, J. F., & Broerse, J. E. W. (2011). Patient‐
expert partnerships in research: How to stimulate inclusion of pa‐
tient perspectives. Health Expectations, 14(3), 225–239. https://doi.
org/10.1111/j.1369‐7625.2010.00647.x
Faulkner, A., & Nicholls, V. (2001). Strategies for Living. Journal of Integrated 
Care, 9(1), 32–36. https://doi.org/10.1108/14769018200100006
Frodin,	U.,	 Lotfi,	K.,	 Fomichov,	V.,	 Juliusson,	G.,	&	Borjeson,	S.	 (2015).	
Frequent and long‐term follow‐up of health‐related quality of life fol‐
lowing allogeneic haematopoietic stem cell transplantation. European 
Journal of Cancer Care, 24(6), 898–910. https://doi.org/10.1111/
ecc.12350
Goodare,	H.,	&	Smith,	R.	(1995).	The	rights	of	patients	in	research.	BMJ, 
310, 1277–1278. https://doi.org/10.1136/bmj.310.6990.1277
Green,	 J.,	 &	 Thorogood,	 N.	 (2004).	 Analysing	 qualitative	 data. In 
Qualitative methods for health research (pp. 173–200). London, UK: 
SAGE.
Kim, P. (2007). Cost of cancer care: The patient perspective. Journal of Clinical 
Oncology, 25(2),	228–232.	https://doi.org/10.1200/JCO.2006.07.9111
Miller,	K.	D.,	Siegel,	R.	L.,	Lin,	C.	C.,	Mariotto,	A.	B.,	Kramer,	J.	L.,	Rowland,	
J. H., Jemal, A. (2016). Cancer treatment and survivorship statistics, 
2016. CA: A Cancer Journal for Clinicians, 66(4), 271–289. https://doi.
org/10.3322/caac.21349
Nierse,	C.	J.,	&	Abma,	T.	A.	(2011).	Developing	voice	and	empowerment:	
The first step towards a broad consultation in research agenda set‐
ting. Journal of Intellectual Disability Research, 55(4), 411–421. https://
doi.org/10.1111/j.1365‐2788.2011.01388.x
Pittens, C. A. C. M. (2013). Knowledge co‐production in health research, pol‐
icy and care practice’s.	Hertogenbosch,	the	Netherlands:	BOXPress.
Pittens, C. A. C. M., Elberse, J. E., Visse, M., Abma, T. A., & Broerse, J. 
E. W., (2014). Research agendas involving patients: Factors that fa‐
cilitate or impede translation of patients’ perspectives in program‐
ming and implementation. Science and Public Policy, 41(6), 809–820. 
https://doi.org/10.1093/scipol/scu010
Popay,	 J.,	&	Williams,	G.	 (1996).	Public	health	 research	and	 lay	knowl‐
edge. Social Science and Medicine, 42(5), 759–768. https://doi.
org/10.1016/0277‐9536(95)00341‐X
Regeer,	B.	J.,	&	Bunders,	J.	F.	G.	(2009).	Knowledge co‐creation: Interaction 
between science and society.	The	Hague,	The	Netherlands:	RMNO.
Siegel,	 R.	 L.,	Miller,	 K.	D.,	 &	 Jemal,	 A.	 (2016).	 Cancer	 statistics.	CA: A 
Cancer Journal for Clinicians, 66(1), 7–30. https://doi.org/10.3322/
caac.21332
Stenberg, U., Ruland, C., & Miaskowski, C. (2010). Review of the literature 
on the effects of caring for a patient with cancer. Psycho‐Oncology, 
19(10), 1013–1025. https://doi.org/10.1002/pon.1670
Telford, R., Beverley, C. A., Cooper, C., & Boote, J. (2002). 
Consumer involvement in health research: Fact or fiction? 
British Journal of Clinical Governance, 7(2), 92–103. https://doi.
org/10.1108/14664100210427606
van	Merode,	T.,	Bours,	S.,	van	Steenkiste,	B.,	Sijbers,	T.,	van	der	Hoek,	G.,	
Vos,	C.,	…	van	der	Weijden,	T.	(2016).	Describing	patients’	needs	in	
the context of research priorities in patients with multiple myeloma 
or Waldenstrom’s disease: A truly patient‐driven study. Zeitschrift Für 
Evidenz, Fortbildung Und Qualität Im Gesundheitswesen, 112, 11–18. 
https://doi.org/10.1016/j.zefq.2016.01.005
Williamson, C. (2001). What does involving consumers in research mean? 
Quarterly Journal of Medicine, 94(12), 661–664.
Williams,	S.	J.,	Martin,	P.,	&	Gabe,	J.	 (2011).	The	pharmaceuticalisation	
of society? A framework for analysis. Sociology of Health and Illness, 
33(5), 710–725. https://doi.org/10.1111/j.1467‐9566.2011.01320.x
Zucca,	A.,	Sanson‐Fisher,	R.,	Waller,	A.,	Carey,	M.,	&	Boadle,	D.	(2017).	
The first step in ensuring patient‐centred quality of care: Ask the 
patient. European Journal of Cancer Care, 26, 1–13. https://doi.
org/10.1111/ecc.12435
How to cite this article:	Schölvinck	A‐FM,	de	Graaff	BMB,	
van den Beld MJ, Broerse JEW. Research in haematological 
cancers: What do patients in the Netherlands prioritise?. Eur J 
Cancer Care. 2019;e12989. https://doi.org/10.1111/
ecc.12989
